Why the study?
The study was conducted to assess the risk of in-hospital mortality due to cancer and chronic comorbidities in post-PCI patients.
Does comorbid cancer increase the risk of in-hospital mortality in adult patients undergoing percutaneous coronary intervention?
Does comorbid cancer increase the risk of in-hospital mortality in adult patients undergoing percutaneous coronary intervention?
Comorbid cancer is an independent risk factor that nearly doubles the risk of in-hospital mortality in patients undergoing percutaneous coronary intervention.
Cancer comorbidity was associated with higher post-PCI in-hospital mortality; leaves open whether it should alter periprocedural risk stratification.
Objectives The primary goal of this inpatient study is to assess the risk of in-hospital mortality due to cancer and chronic comorbidities in post-percutaneous coronary intervention (PCI) patients. Methods We conducted a retrospective cross-sectional study, including 1,131,415 adult patients (age +18 years) by using the Nationwide Inpatient Sample (NIS) from 2012 to 2014. These patients underwent PCI, and they were further sub-grouped by the co-diagnosis of cancer. Logistic regression analysis was used to evaluate the risk of association between comorbid cancer and in-hospital mortality in post-PCI inpatients. Results Most PCI inpatients with cancer were older adults (mean age 70.6 years), males (71.8%), and white (80.6%). Post-PCI mortality risk was 1.28 times higher in females (95% CI 1.235 - 1.335) as compared to males. Coagulopathy and anemias significantly increased the risk of post-PCI mortality by three times (95% CI 2.837 - 3.250) and 1.6 times (95% CI 1.534 - 1.692), respectively. Comorbid cancer was associated with an increased risk of in-hospital mortality in post-PCI patients by 1.9 times (95% CI 1.686 - 2.086) after controlling for demographic confounders and chronic comorbidities. Conclusion Our analysis showed that cancer is an independent risk factor for in-hospital mortality after PCI. This association calls for an integrated care model in the management of a complex patient population with cancer and other comorbidities requiring more vigilance and aggressive management.
No takes yet. Share an insight, caveat, or question.
Gaddam et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: